The Guardian·3 min read·medium

AI sell-off deepens as chip stocks slump in market retreat - business live

L
Lauren Almeida, Sarah Butler, Graeme Wearden
AI sell-off deepens as chip stocks slump in market retreat - business live
AI Summary

Pharmaceutical giant GSK is relocating its main R&D hub from Stevenage to a new facility in Cambridge by 2029 as part of a £400 million investment. The move is expected to integrate the company into the Cambridge Biomedical Campus while prompting internal restructuring and potential job cuts.

GSK mock-up of new R&D centre under development in Cambridge Illustration: GSK GSK has announced it will shut its main research and development hub in Stevenage and open a new site in Cambridge.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesssciencehealth

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in